胃肠道 stromal 瘤与低血糖的临床特征
Akihiko Chida1, Kenta Kawasaki1, Junko Kuramoto2
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo 160-8582, Japan.
胃肠道 stromal 瘤 (GISTs) 可能导致低血糖症,影响4.1%的患者. 在GIST中反复出现的低血糖症表明预后不佳,特别是当与由IGF-II放大驱动的非岛屿细胞瘤低血糖症 (NICTH) 相联系时.
科学领域:
- 在瘤学瘤学.
- 内分泌学 在内分泌学.
- 病理学 病理学 病理学
背景情况:
- 氨酸激酶抑制剂改善了胃肠道 stromal 瘤 (GIST) 的存活率.
- 然而,由于个体状况,包括低血糖症,一些患者没有受益.
- 在GIST的低血糖症,以头和出汗等症状为特征,可以源于转移,药物效应,并发症或非岛屿细胞瘤低血糖症 (NICTH).
研究的目的:
- 调查GIST患者低血糖的患病率,预后和原因.
- 为了分析由于GIST中NICTH导致的复发性低血糖症的罕见病例.
- 通过组织学和遗传分析来描述NICTH-GIST.
主要方法:
- 在单一机构对GIST患者患有低血糖症的回顾性分析.
- 尸体解剖和基因测序的患者,由于NICTH的复发性低血糖.
- 对存档的瘤样本进行时间分析.
主要成果:
- 低血糖事件发生在4.1%的GIST患者中.
- 复发性低血糖症与预后不佳有关.
- 一个NICTH-GIST病例揭示了组织多样性和胰岛素样生长因子II (IGF-II) 放大.
- IGF-II表达可能发生在瘤发育的早期.
结论:
- 低血糖症的GIST是一种显著的临床疾病,患病率为4.1%.
- 在GIST患者中反复出现低血糖症预示着预后不佳.
- NICTH-GIST的特点是组织多样性和IGF-II放大,可能起源于瘤发育的早期阶段.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
05:16Laparoscopy-endoscopy Cooperative Surgery for the Treatment of Gastric Gastrointestinal Stromal Tumors
Published on: February 19, 2022
相关概念视频
Hypoglycemia and Glucagon
Glucose Transporters
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Diabetes Mellitus: Type 2 and Gestational
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: Glinides
Pathophysiology of Diabetes
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
